NK‐ and T‐cell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of anti‐CTLA‐4 therapy
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Malignant mesothelioma (MM) is a highly aggressive form of cancer with limited treatment options. Although the role of NK cells has been studied in many solid tumors, the pattern of NK‐cell subsets and their recognition of mesothelioma cells remain to be explored. We used RNA expression data of MM biopsies derived from the cancer genome atlas to evaluate the immune cell infiltrates. We characterized the phenotype of circulating NK and T cells of 27 MM patients before and after treatment with an anti‐CTLA‐4 antibody (tremelimumab). These immune cell profiles were compared to healthy controls. The RNA expression data of the MM biopsies indicated the presence of NK cells in a subgroup of patients. We demonstrated that NK cells recognize MM cell lines and that IL‐15 stimulation improved NK cell‐mediated lysis in vitro. Using multivariate projection models, we found that MM patients had a perturbed ratio of CD56 bright and CD56 dim NK subsets and increased serum concentrations of the cytokines IL‐10, IL‐8 and TNF‐α. After tremelimumab treatment, the ratio between the CD56 bright and CD56 dim subsets shifted back towards physiological levels. Furthermore, the improved overall survival was correlated with low TIM‐3+CD8+ T‐cell frequency, high DNAM‐1+CD56 dim NK‐cell frequency and high expression levels of NKp46 on the CD56 dim NK cells before and after immune checkpoint blockade. Together, our observations suggest that NK cells infiltrate MM and that they can recognize and kill mesothelioma cells. The disease is associated with distinct lymphocytes patterns, some of which correlate with prognosis or are affected by treatment with tremelimumab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments
Barry, K. C., Hsu, J., Broz, M. L., Cueto, F. J., Binnewies, M., Combes, A. J., Nelson, A. E., Loo, K., Kumar, R., Rosenblum, M. D., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0085-8 · Cited by 1,021
Zalcman, G., Mazieres, J., Margery, J., Greillier, L., Audigier-Valette, C., Moro-Sibilot, D., Molinier, O., Corre, R., Monnet, I., Gounant, V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01238-6 · Cited by 968
Romano, E., Kusio-Kobialka, M., Foukas, P. G., Baumgaertner, P., Meyer, C., Ballabeni, P., Michielin, O., Weide, B., Romero, P., & Speiser, D. E. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417320112 · Cited by 601
Meloni, F., Morosini, M., Solari, N., Passadore, I., Nascimbene, C., Novo, M., Ferrari, M., Cosentino, M., Marino, F., Pozzi, E., et al. (2006) · Human Immunology · doi:10.1016/j.humimm.2005.11.005 · Cited by 169 · cited 1×
“showed that this specific subset has immunosuppressive characteristics in lung cancer and MM patients.(36) The observed increase in peripheral CD8 CD57 T cells in patients is therefore intriguing and deserves further investigation.”
Backgroundde Coaña, Y. P., Wolodarski, M., Poschke, I., Yoshimoto, Y., Yang, Y., Nyström, M., Edbäck, U., Brage, S. E., Lundqvist, A., Masucci, G. V., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15368 · Cited by 139
Cited by
The cancer–natural killer cell immunity cycle
Huntington, N. D., Cursons, J., & Rautela, J. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0272-z · Cited by 566
The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy
Chu, G. J., van Zandwijk, N., & Rasko, J. E. J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01366 · Cited by 70
Immunotherapy for Mesothelioma: A Critical Review of Current Clinical Trials and Future Perspectives
Gray, S. G., & Mutti, L. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.11.23 · Cited by 58
“Moreover, an analysis of a small cohort of patients treated with anti-CTLA4 demonstrated that improved OS was correlated with low TIM-3+ CD8+ T-cell frequency (73), raising the possibility that we may be able to refine our ability to predict patients that will respond to specific immune checkpoint blockade strategies…”
BackgroundThe Immune Microenvironment of Malignant Pleural Mesothelioma: A Literature Review
Désage, A.-L., Karpathiou, G., Peoc’h, M., & Froudarakis, M. E. (2021) · Cancers · doi:10.3390/cancers13133205 · Cited by 34
“As an assessment of immunotolerance in the microenvironment, a strong correlation was found between the expression of TIM-3 and PDL-1 on TILs in the stroma (RR = 0.48; p < 0.001) [40].”
BackgroundInfluential
Metadata
- Authors
- Sottile, R., Tannazi, M., Johansson, M. H., Cristiani, C. M., Calabró, L., Ventura, V., Cutaia, O., Chiarucci, C., Covre, A., Garofalo, C., Pontén, V., Tallerico, R., Frumento, P., Micke, P., Maio, M., Kärre, K., & Carbone, E.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2019-05-13
- Volume
- 145
- Issue
- 8
- Pages
- 2238-2248
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2941053886
- Cited by
- 38
- References
- 5
- FWCI
- 1.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: NK‐ and T‐cell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of anti‐CTLA‐4 therapy. https://app.cochat.ai/papers/10.1002/ijc.32363
- The paper
- Sottile, R., Tannazi, M., Johansson, M. H., Cristiani, C. M., Calabró, L., Ventura, V., Cutaia, O., Chiarucci, C., Covre, A., Garofalo, C., Pontén, V., Tallerico, R., Frumento, P., Micke, P., Maio, M., Kärre, K., & Carbone, E. (2019). NK‐ and T‐cell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of anti‐CTLA‐4 therapy. International Journal of Cancer. https://doi.org/10.1002/ijc.32363
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.